《大行報告》匯豐研究下調海天國際(01882.HK)目標價至31.5元 評級「買入」
匯豐研究發表報告,下調海天國際(01882.HK)目標價,由33元降至31.5元,評級維持「買入」。
該行指,去年因疫情影響注塑機的海外產能,海天國際已經見本地到較小型的款式增長。至5月,公司新訂單依然按月減少,主因小型中型客戶擔心環球經濟重啟,過去移至國內的訂單將返回海外,因而下調資本開支。不過,大型款式需求仍然強勁,特別是來自自動駕駛和大型家電客戶,公司料目前的訂單可支持至第三季表現。
該行又指,公司今年初調高產品均價3至5%,近期於內地再升2至3%,海外升5%,以反映原材料成本和人民幣升值,但料毛利會繼續受壓,因未能完全補償過去較低價的訂單。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.